Modern acne treatment;Moderne aknetherapie

Aktuelle Dermatologie

Volumn 29, Issue 1-2, 2003, Pages 49-57

  Zouboulis, Christos C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTIANDROGEN; ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CHLORMADINONE ACETATE; CLINDAMYCIN; CLINDAMYCIN PLUS ERYTHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYPROTERONE ACETATE; DEXAMETHASONE; DIANE; DOXYCYCLINE; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUTAMIDE; HORMONE; ISOTRETINOIN; MESTRANOL; METRONIDAZOLE; MINOCYCLINE; MOTRETINIDE; PREDNISOLONE; RETINOIC ACID; RETINOID; SPIRONOLACTONE; TAZAROTENE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ACNE FULMINANS; AGE DISTRIBUTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CANDIDIASIS; CORTICOSTEROID THERAPY; DEPRESSION; DISEASE CLASSIFICATION; DISEASE SEVERITY; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HEPATITIS; HIRSUTISM; HUMAN; HYPERPIGMENTATION; INFLAMMATION; LOW DRUG DOSE; MENSTRUATION DISORDER; NEPHRITIS; PREVALENCE; PSEUDOMEMBRANOUS COLITIS; PUBERTY; REVIEW; SCAR FORMATION; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037231755     PISSN: 03402541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38236     Document Type: Review

References (76)

1. Gollnick H, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol 1991; 18: 489-499
2. Brown SK, Shalita AR. Acne vulgaris. Lancet 1998; 351: 1871-1876
3. Zouboulis CC. Acne: Current aspects on pathology and treatment. Dermatol Experiences 1999; 1: 6-37
4. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206: 37-53
5. Cunliffe WJ, Eady EA. A reappraisal and update on the pathogenesis and treatment of acne. Cur Opin Infect Dis 1992; 5: 703-710
6. Dreno B, Poli F. Epidemiology of acne. Dermatology 2003; 206: 7-10
7. Stern R. Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol 2000; 43: 1042-1048
8. Leyden JJ. Therapy for acne vulgaris. N Engl J Med 1997; 336: 1156-1162
9. Zouboulis CC, Fimmel S, Ortmann J, Turnbull JR, Boschnakow A, Pochi PE. Sebaceous Glands. In: Hoath SB, Maibach H (Hrg). Neonatal Skin-Structure and Function. 2nd ed. New York, Basel: Marcel Dekker, in press
10. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Dermatology 2003; 206: 11-16
11. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance- A world wide problem. Dermatology 2003; 206: 54-56
12. Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology 2001; 203: 277-279
13. Green J, Sinclair RD. Perceptions of acne vulgaris in final year medical student written examination answers. Australas J Dermatol 2001; 42: 98-101
14. Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology 2003; 206: 24-28
15. Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, Scherbaum WA, Orfanos CE, McCann SM, Bornstein SR. Corticotropin releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA 2002; 99: 7148-7153
16. Toyoda M, Morohashi M. New aspects in acne inflammation. Dermatology 2003; 206: 17-23
17. O'Brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. J Dermatol Treat 1998; 9: 215-220
18. Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, Kligman AM, Leyden JJ, Lookingbill DP, Plewig G et al. Report of the consensus conference on acne classification. J Am Acad Dermatol 1991; 24: 495-500
19. Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, Gollnick H, Layton AM, Leyden JJ, Mascaro JM, Ortonne JP, Shalita A. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351-357
20. Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. Horm Res 2000; 54: 251-258
21. Thiboutot DM. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol 2001; 15: 57-61
22. Madden WS, Landells ID, Poulin Y, Searles GE, Smith KC, Tan JK, Toole J, Zip CM, Degreef H. Treatment of acne vulgaris and prevention of acne scarring: Canadian consensus guidelines. J Cutan Med Surg 2000; 4: 2-13
23. Kaminsky A. Less common methods to treat acne. Dermatology 2003; 206: 68-73
24. Gollnick HPM, Krautheim A. Topical treatment in acne: Current status and future aspects. Dermatology 2003; 206: 29-36
25. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196: 119-125
26. Orfanos C, Ehlert R, Gollnick H. The retinoids - at review of their clinical pharmacology and therapeutic use. Drugs 1987; 34: 459-503
27. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-388
28. Brogden RN, Goa KE. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997; 53: 511-519
29. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196: 130-134
30. Berson DS, Shalita AR. The treatment of acne: The role of combination therapies. J Am Acad Dermatol 1995; 32: 31-41
31. Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology 1998; 196: 135-139
32. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001; 15: 51-55
33. Chosidow O, Poll F, Naline E, Advenier C, Revuz J. Comedonal diffusion of minocycline in acne. Dermatology 1998; 196: 162
34. Colvin JH, Sheth AP. Minocycline hypersensitivity syndrome with hypotension mimicking septic shock. Pediatr Dermatol 2001; 18: 295-298
35. Kiessling S, Forrest K, Moscow J, Gewirtz A, Jackson E, Roszman T, Goebel J. Interstitial nephritis, hepatic failure, and systemic eosinophilia after minocycline treatment. Am J Kidney Dis 2001; 38: 36
36. Seaman HE, Lawrenson RA, Williams TJ, MacRae KD, Farmer RD. The risk of liver damage associated with minocycline: a comparative study. J Clin Pharmacol 2001; 41: 852-860
37. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11: 538-544
38. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998; 196: 140-147
39. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris - 10 years later: A safe and successful treatment. Br J Dermatol 1993; 129: 292-296
40. Lehucher-Cheyrac DS, Weber-Buisset MJ. Isotretinoin and acne in practice: at prospective analysis of 188 cases over 9 years. Dermatology 1993; 186: 123-128
41. Leyden JJ, McGinley KJ, Foglia AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol 1986, 86: 390-393
42. Tsukada M, Schröder M, Roos TC, Chandraratna RAS, Reichert U, Merk HF, Orfanos CE, Zouboulis CC. 13-cis Retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 2000; 115: 321-327
43. Stainforth JM, Layton AM, Taylor JP, Curiliffe WJ. Isotretinoin for the treatment of acne vulgaris: Which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297-301
44. Karvonen SJ. Acne fulminans. Report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993; 28: 572-579
45. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106
46. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26: 599-606
47. Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 2002; 204: 232-235
48. Margolis DJ, Attie M, Leyden JJ. Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 1996; 132: 769-774
49. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003; 206: 57-67
50. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism - Basic research and clinical perspectives. J Invest Dermatol 2002, 119: 992-1007
51. Shaw JC. Hormonal therapies in acne. Expert Opin Pharmacother 2002; 3: 865-874
52. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001; 116: 793-800
53. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 2002; 57: 231-234
54. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69: 2-15
55. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203: 38-44
56. Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998; 196: 148-152
57. Schmidt JB. Other antiandrogens. Dermatology 1998; 196: 153-157
58. Dodin S, Faure N, Cedrin I, Mechain C, Turcot-Lemay L, Guy J, Lemay A. Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopatic hirsutism. Clin Endocrinol (Oxf.) 1995; 43: 578-582
59. Lubbos HG, Hasinski S, Rose LI, Pollock J. Adverse effects of spironolactone therapy in women with acne. Arch Dermatol 1998; 134: 1162-1163
60. Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 1999; 141: 307-309
61. Bass D, Zouboulis CC. Behandlung der Acne fulminans mit Isotretinoin und Prednisolon. Z Hautkr 2001; 76: 473
62. Vexiau P, Baspeyras M, Chaspoux C, Foin N, Allaert FA, Abramovici Y. Acne in adult women: data from a national study on the relationship between type of acne and markers of clinical hyperandrogenism. Ann Dermatol Venereol 2002; 129: 174-178
63. Koreck A, Pivarcsi A, Dobozy A, Kemény L. The Role of Innate Immunity in the Pathogenesis of Acne. Dermatology 2003; 206: 96-105
64. Zouboulis CC, Nestoris S, Adler YD, Picardo M, Camera E, Orth M, Orfanos CE, Cunliffe WJ. A new concept for acne therapy - A pilot study with Zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003; 139:im Druck
65. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, Lowe NJ, Jones TM, Stewart DM, Jarratt MT, Katz I, Pariser DM, Pariser RJ, Tschen E, Chalker DK, Rafal ES, Savin RP, Roth HL, Chang LK, Baginski DJ, Kempers S, McLane J, Eberhardt D, Leach EE, Bryce G, Hong J. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001; 45: 187-195
66. Akamatsu H, Tomita T, Horio T. Effects of roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology 2002; 204: 277-280
67. Inui S, Nakajima T, Fukuzato Y, Fujimoto N, Chang C, Yoshikawa K, Itami S. Potential anti-androgenic activity of roxithromycin in skin. J Dermatol Sci 2001; 27: 147-151
68. Lemay A, Dewailly SD, Grenier R, Huard J. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,I-norgestrel. J Clin Endocrinol Metabolism 1990; 71: 8-14
69. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 2001; 76: 461-468
70. Vree ML, Schmidt J. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care 2001; 6: 108-114
71. Maloney M, Arbit D, Flack M, McLaughlin-Miley C, Sevilla C, Derman R. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Women's Health 2001; 1: 124-131
72. Lucky A, Henderson T, Olson W, Robisch D, Lebwohl M, Swinyer L. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746-754
73. Pugeat M, Ducluzeau PH. Insulin resistance, polycystic ovary syndrome and metformin. Drugs 1999; 58: 41-46
74. Chen W-C, Zouboulis CC, Orfanos CE. The 5α-reductase system and its inhibitors; recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177-184
75. Cilotti A, Danza G, Serio M. Clinical application of 5alpha-reductase inhibitors. J Endocrinol Invest 2001; 24: 199-203
76. Fimmel S, Saborowski A, Bogdanoff B, Orfanos CE, Zouboulis CC. Inhibition of androgen receptor expression and of androgen activity on human sebocytes by antisense oligonucleotides. Ann Dermatol Venereol 2002; 129: 375